Key Paroxysmal Nocturnal Hemoglobinuria Treatment Market Players:
- AstraZeneca
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Apellis Pharmaceuticals Inc.
- Novartis
- Chugai Pharmaceuticals
- Roche
- UCB
- Regeneron Pharmaceuticals
The global paroxysmal nocturnal hemoglobinuria treatment market is projected for a robust growth curve during the forecast period. Key market players are tying up with local distributors to penetrate new markets and invest in research and development to increase the efficacy of treatment.
Here are some key players in the market:
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of paroxysmal nocturnal hemoglobinuria treatment is assessed at USD 5.49 billion.
Paroxysmal Nocturnal Hemoglobinuria Treatment Market size was valued at USD 5 billion in 2025 and is expected to reach USD 13.94 billion by 2035, registering around 10.8% CAGR during the forecast period i.e., between 2026-2035.
North America commands a 47.2% share in the Paroxysmal Nocturnal Hemoglobinuria Treatment Market, driven by high adoption rate of advanced therapies and a robust regulatory framework, ensuring growth through 2035.
Key players in the market include AstraZeneca, Apellis Pharmaceuticals Inc., Novartis, Chugai Pharmaceuticals, Roche, UCB, Regeneron Pharmaceuticals.
